IGEA Pharma NV / Key word(s): Annual results/Annual results
09-Aug-2022 / 00:30 CET/CEST
Publication of an ad hoc announcement pursuant to Art. 53LR
The issuer is solely responsible for the content of this announcement.
IGEA to obtain further approval from SIX for the publication of the 2021 annual report
Hoofddorp, The Netherlands, August 09, 2022. IGEA Pharma NV (SIX: IGPH) announced today that it has been granted a temporary exemption from its publication obligations regarding the 2021 annual report.
At the request of the Statutory Auditors, even if the 2021 annual report is completed, additional time for the review and drafting of the Statutory Auditor’s report is necessary.
As approved by SIX, this press release reproduces the relevant part of the decision:
“I. The request for exemption from IGEA (Issuer) dated July 25, 2022 requesting a
extension of the deadline for publishing its 2021 annual report and filing this report with
SIX Exchange Regulation AG until August 31, 2022 at the latest is granted from
Issuers Committee of the Regulatory Board with the following reservation (lit. a and b) and under the following conditions (lit. c):
Since the deadline for publication of the 2021 annual report and filing of this report with
SIX Exchange Regulation AG has been extended several times, it should be noted
that the extension is granted for the last time until August 31, 2022.
The suspension of trading in the registered shares of the Issuer remains in force
until the publication of the 2021 annual report in accordance with the provisions relating to event advertising (Art. 53 of the Listing Rules [LR] in connection with the directive on event advertising [DAH]) and filed with SIX Exchange Regulation AG.
The IGEA is required to publish a notice in accordance with the provisions on publicity
occasional publicity (art. 53 LR in relation to the DAH) concerning this decision
until Tuesday, August 09, 2022, 07:30 CET, at the latest. The notice must
– the reproduction without modification of the wording of para. I. of this decision,
placed in a prominent position;
– the reasons for the Issuer’s request for a third party
Extension of the deadline for publication of its 2021 annual report and filing
said declaration to SIX Exchange Regulation AG”
About the IGEA
IGEA Pharma NV focuses, through its joint venture, on industrial supercritical CO2 extraction of CBD and other valuable components from their plant matrices for health prevention, pharmacy, food and pharmaceuticals. beverages and other selected industries, with an innovative and highly diversifiable business pipeline. The company aims to become a center of excellence in highly controlled plant matrices and their industrial extraction technology. On the other hand, Igea operates in health technology preventive products and devices, marketing an Alzheimer’s disease prevention kit (which
includes ‘Alz1’, a home laboratory test kit to measure unbound copper in the blood and a natural dietary supplement brand ‘Alz1 Tab’ designed to reduce the level of heavy metals in the blood) and plans to integrate
the pipeline based on the detection of unbound copper with prevention of type II diabetes in the near future. IGEA also markets a rapid COVID19 test for the detection of IgM and IgG antibodies related to SARSCoV-2.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
Vincenzo Moccia, CEO, +393405830933
This document does not constitute an offer to purchase or subscribe for securities and either this document
nor should any part of it form the basis of any investment decision in IGEA. The information contained
in this press release has been carefully prepared. However, IGEA neither assumes nor assumes any responsibility for
regardless of the nature of the accuracy and completeness of the information provided here. The IGEA does not
assume an obligation of any kind to update or correct the information contained in this press release
whether as a result of new information, future events or for other reasons. This publication may contain
Specific forward-looking statements and assessments or intentions regarding IGEA and its business.
These forward-looking statements are subject to known and unknown risks, uncertainties and other factors.
which may result in a substantial difference between the actual results, the financial situation, the evolution,
or the performance of IGEA and those explicitly or implicitly assumed in these declarations. Against the
In the context of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes
no responsibility to update forward-looking statements or to adapt them to future events or developments,
except as required by law.
End of privileged information